Form 8-K - Current report:
SEC Accession No. 0001558370-24-002312
Filing Date
2024-03-04
Accepted
2024-03-04 07:30:13
Documents
18
Period of Report
2024-03-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrbo-20240304x8k.htm   iXBRL 8-K 59565
2 EX-10.1 nrbo-20240304xex10d1.htm EX-10.1 156697
3 EX-99.1 nrbo-20240304xex99d1.htm EX-99.1 15863
4 GRAPHIC nrbo-20240304x8k001.jpg GRAPHIC 12152
5 GRAPHIC nrbo-20240304xex99d1001.jpg GRAPHIC 11132
  Complete submission text file 0001558370-24-002312.txt   442687

Data Files

Seq Description Document Type Size
6 EX-101.SCH nrbo-20240304.xsd EX-101.SCH 3145
7 EX-101.LAB nrbo-20240304_lab.xml EX-101.LAB 15264
8 EX-101.PRE nrbo-20240304_pre.xml EX-101.PRE 9670
19 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20240304x8k_htm.xml XML 4649
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 24712850
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)